Artificial Golgi Reactor for Tailoring Glycans

Reference number 10810

Sectors: Medtech

Industries:

A novel platform comprising immobilized enzymes to produce homogenously glycosylated proteins for therapeutic or diagnostic applications.

Proposed use

Researchers at Imperial have developed a novel platform, the Artificial Golgi Reactor, to address the heterogeneous sugar profile of antibodies in a cell-free environment. The platform consists of sequential reactions utilizing immobilized glycosylation enzymes that are spatially separated to avoid glycan heterogeneity.

Problem addressed

Therapeutic proteins, such as monoclonal antibodies (mAbs), are used as an effective drug against cancer, autoimmune disorders and for bacterial and viral infections. Glycosylation, the post-translational enzymatic addition of sugars, is a key quality attribute of proteins known to affect drug functionality, stability and efficacy. However, as therapeutic proteins are primarily produced in cell-based systems, there is a large degree of sugar heterogeneity owing to enzyme competition, the lack of orderly reactions and limited availability of reaction components. The heterogeneous glycan profile leads to mixture of product structures with different stability and efficacy characteristics.

Technology overview

The tightly controlled reaction conditions in the Artificial Golgi Reactor allow the production of highly homogeneous (>95%) mAbs and other therapeutic proteins. This novel strategy is applied post-expression and can be coupled with various expression systems (e.g. Chinese hamster ovary (CHO), human embryonic kidney (HEK), Pichia pastoris cells etc.) to fine-tune the glycan structures of protein therapeutics. Importantly, the system can be used to tailor the glycan profile of biosimilars and biobetters in accordance with regulatory requirements.

Benefits

  • The design is modular and can be adapted for any desired sugar composition
  • The design can be used as plug-and-play approach to add sugars on proteins derived from cell-based or cell-free systems
  • Increased system stability due to immobilised enzymes allowing long term storage without significant loss of activity
  • Immobilisation allows enzyme reusability for multiple reactions, lowering the cost and offering a sustainable solution

Intellectual property information

Priority Application Greece (Number: 20210100201)
Supplemental Application United Kingdom (Number: 2106646.9)

Inventors

Portrait of Professor Cleo Kontoravdi
Professor Cleo Kontoravdi

Professor of Biological Systems Engineering
Faculty of Engineering, Department of Chemical Engineering

Visit personal site
Portrait of Professor Stuart Haslam
Professor Stuart Haslam

Professor in Structural Glycobiology
Faculty of Natural Sciences, Department of Life Sciences

Visit personal site
Portrait of Professor Karen Polizzi
Professor Karen Polizzi

Professor of Biotechnology
Faculty of Engineering, Department of Chemical Engineering

Visit personal site

Contact us about this technology



Contact

Dr Valeska Gonzalez

Industry Partnerships and Commercialisation Executive, Engineering

Dr Valeska Gonzalez is Industry Partnerships and Commercialisation Executive for the Faculty of Engineering at Imperial College London

Contact Valeska

+44 (0)20 7594 6893

v.gonzalez-montilla@imperial.ac.uk

Related technologies

Artificial Golgi Reactor for Tailoring Glycans

Artificial Golgi Reactor for Tailoring Glycans

A novel platform comprising immobilized enzymes to produce homogenously glycosylated proteins for therapeutic or diagnostic applications. Find out more

Data-driven Multiplexing for Accurate Gene Detection

Data-driven Multiplexing for Accurate Gene Detection

Machine learning approach for high-level multiplexing in qPCR and dPCR, up to 21-plex demonstrated Find out more

Sign up for updates

Sign up for monthly technology alerts via email, and find other ways to connect with us.

Loading...